What's Hot

    Adding Lilly’s new drug to Zepbound helped individuals lose as much as 23% of their weight. But there have been extra uncomfortable side effects. | Invesloan.com

    September 30, 2026

    Some 2026 midterm candidates are distancing from AOC’s endorsement | Invesloan.com

    September 30, 2026

    Uber Wait Times Rise 19% As Prices Climb 53%: Study | Invesloan.com

    September 30, 2026
    Facebook Twitter Instagram
    Finance Pro
    Facebook Twitter Instagram
    invesloan.cominvesloan.com
    Subscribe for Alerts
    • Home
    • News
    • Politics
    • Money
    • Personal Finance
    • Business
    • Economy
    • Investing
    • Markets
      • Stocks
      • Futures & Commodities
      • Crypto
      • Forex
    • Technology
    invesloan.cominvesloan.com
    Home » Adding Lilly’s new drug to Zepbound helped individuals lose as much as 23% of their weight. But there have been extra uncomfortable side effects. | Invesloan.com
    News

    Adding Lilly’s new drug to Zepbound helped individuals lose as much as 23% of their weight. But there have been extra uncomfortable side effects. | Invesloan.com

    September 30, 2026Updated:September 30, 2026
    Share
    Facebook Twitter LinkedIn Pinterest Email


    The company is working on an experimental amylin drug to see if it can help people lose weight and manage their diabetes — much like a GLP-1.

    Share. Facebook Twitter Pinterest LinkedIn Tumblr Email

    Keep Reading

    Major automotive rivals are teaming as much as resolve the largest EV roadblock: Reliable charging | Invesloan.com

    Abbott launches “SimpleScreen” blood take a look at to increase most cancers screening | Invesloan.com

    ‘I’m afraid of human stupidity’: Why this prime economist prefers U.S. tech and gold over bonds | Invesloan.com

    BlackSky to provide satellite tv for pc imagery for Robinhood agent App (BKSY:NYSE) | Invesloan.com

    One group of funds is holding up the inventory market. Barclays says oil costs should fall to drive a year-end rally. | Invesloan.com

    Burry says markets 'ought to tank laborious' to forestall OpenAI, Anthropic IPOs | Invesloan.com

    AbbVie studies constructive section 2 information for Zumilokibart in atopic dermatitis | Invesloan.com

    ArcelorMittal eyes $961M enlargement of Brazilian metal mill (MT:NYSE) | Invesloan.com

    Japan’s industrial output drops 1.7% M/M in Aug;retail gross sales rise 2.7% | Invesloan.com

    LATEST NEWS

    Adding Lilly’s new drug to Zepbound helped individuals lose as much as 23% of their weight. But there have been extra uncomfortable side effects. | Invesloan.com

    September 30, 2026

    Some 2026 midterm candidates are distancing from AOC’s endorsement | Invesloan.com

    September 30, 2026

    Uber Wait Times Rise 19% As Prices Climb 53%: Study | Invesloan.com

    September 30, 2026

    Major automotive rivals are teaming as much as resolve the largest EV roadblock: Reliable charging | Invesloan.com

    September 30, 2026
    POPULAR

    China’s first passenger jet completes maiden commercial flight

    May 28, 2023

    Numbers taking US accountancy exams drop to lowest level in 17 years

    May 29, 2023

    Toyota chair faces removal vote over governance issues

    May 29, 2023
    Advertisement
    Load WordPress Sites in as fast as 37ms!
    Facebook Twitter Pinterest WhatsApp Instagram
    © 2007-2023 Invesloan.com All Rights Reserved.
    • Privacy
    • Terms
    • Press Release
    • Advertise
    • Contact

    Type above and press Enter to search. Press Esc to cancel.

    invesloan.com
    Manage Cookie Consent
    To provide the best experiences, we use technologies like cookies to store and/or access device information. Consenting to these technologies will allow us to process data such as browsing behavior or unique IDs on this site. Not consenting or withdrawing consent, may adversely affect certain features and functions.
    Functional Always active
    The technical storage or access is strictly necessary for the legitimate purpose of enabling the use of a specific service explicitly requested by the subscriber or user, or for the sole purpose of carrying out the transmission of a communication over an electronic communications network.
    Preferences
    The technical storage or access is necessary for the legitimate purpose of storing preferences that are not requested by the subscriber or user.
    Statistics
    The technical storage or access that is used exclusively for statistical purposes. The technical storage or access that is used exclusively for anonymous statistical purposes. Without a subpoena, voluntary compliance on the part of your Internet Service Provider, or additional records from a third party, information stored or retrieved for this purpose alone cannot usually be used to identify you.
    Marketing
    The technical storage or access is required to create user profiles to send advertising, or to track the user on a website or across several websites for similar marketing purposes.
    • Manage options
    • Manage services
    • Manage {vendor_count} vendors
    • Read more about these purposes
    View preferences
    • {title}
    • {title}
    • {title}